Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001453687-25-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-06 | 2025-01-02 | RNAC | Davis Blaine | CFO | A - Grant | $0.00 | +22.0K | 102.8K | +27% | $0 |
| D | 2025-01-06 | 2025-01-02 | RNAC | Davis Blaine | CFO | A - Grant | $0.00 | +64.6K | 64.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 22,000 | $0.00 | 102,800 | D | — | — | (F1) Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. (F2) On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-01-02 | A | A | 64,600 | $0.00 | 64,600 | D | $16.93 · — to 2035-01-01 | 64,600 Common Stock | (F3) This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. |